TOLREMO therapeutics AG
TOLREMO therapeutics is a biotech company focused on transforming cancer treatment by targeting transcriptional resistance pathways that lead to drug resistance. Their mission is to develop therapies that prevent cancer cells from evading targeted treatments, with a lead compound TT125-802, a small molecule inhibitor of CBP/p300 bromodomain, currently in clinical trials. The company aims to improve long-term patient outcomes by addressing non-oncogene addiction in cancer, leveraging proprietary phenotypic screening platforms, and advancing innovative combination therapies.
Industries
Nr. of Employees
small (1-50)
TOLREMO therapeutics AG
Patents
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12595258-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12478624-B2
View DetailsCombination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
US-12472179-B2
View Details
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12595258-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12478624-B2
View DetailsCombination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
US-12472179-B2
View DetailsProducts
Oral small-molecule CBP/p300 bromodomain inhibitor (clinical candidate)
An orally available, selective small-molecule inhibitor targeting the bromodomain of CBP/p300 developed to block transcriptional programs that mediate early non-genetic resistance to targeted cancer therapies.
Image-based phenotypic screening platform
A proprietary image-based phenotypic screening platform used to identify small molecules that downregulate non-genetic resistance phenotypes and nominate drug targets.
Oral small-molecule CBP/p300 bromodomain inhibitor (clinical candidate)
An orally available, selective small-molecule inhibitor targeting the bromodomain of CBP/p300 developed to block transcriptional programs that mediate early non-genetic resistance to targeted cancer therapies.
Image-based phenotypic screening platform
A proprietary image-based phenotypic screening platform used to identify small molecules that downregulate non-genetic resistance phenotypes and nominate drug targets.
Services
Discovery and preclinical development of small-molecule therapeutics that inhibit transcriptional mechanisms of drug resistance, using phenotypic screening and medicinal chemistry.
Translation of preclinical findings into clinical biomarker strategies and pharmacodynamic assays to support dose selection and patient stratification.
Discovery and preclinical development of small-molecule therapeutics that inhibit transcriptional mechanisms of drug resistance, using phenotypic screening and medicinal chemistry.
Translation of preclinical findings into clinical biomarker strategies and pharmacodynamic assays to support dose selection and patient stratification.
Expertise Areas
- Phenotypic screening and target discovery
- Epigenetic drug development
- Medicinal chemistry for selective small molecules
- Preclinical oncology models and combination testing
Key Technologies
- Image-based phenotypic screening
- Bromodomain-targeting small-molecule inhibitors
- Epigenetic modulation of transcription
- Preclinical tumor efficacy models
News & Updates
The first patient has been dosed in TOLREMO's Phase 1 clinical trial evaluating TT125-802, a drug aimed at overcoming transcriptional cancer drug resistance.
Jeff Jonker and Mike Sherman join TOLREMO's Board of Directors to support the company's growth and clinical development of TT125-802.
Updated data from TOLREMO's Phase I study of TT125-802 demonstrates deep and durable responses in non-small cell lung cancer.
An article discussing TOLREMO's approach to preventing cancer drug resistance by targeting non-oncogene pathways, specifically transcriptional reprogramming via CBP/p300 inhibition.
An interview series featuring TOLREMO's CEO Stefanie Flückiger-Mangual discussing her journey and scientific work in drug resistance in cancer therapy.
Innovator of the Year 2022
Stefanie Flückiger-Mangual received the Innovator of the Year award at the Female Innovation Forum for her work in cancer drug resistance.
The first patient has been dosed in TOLREMO's Phase 1 clinical trial evaluating TT125-802, a drug aimed at overcoming transcriptional cancer drug resistance.
Jeff Jonker and Mike Sherman join TOLREMO's Board of Directors to support the company's growth and clinical development of TT125-802.
Updated data from TOLREMO's Phase I study of TT125-802 demonstrates deep and durable responses in non-small cell lung cancer.
An article discussing TOLREMO's approach to preventing cancer drug resistance by targeting non-oncogene pathways, specifically transcriptional reprogramming via CBP/p300 inhibition.
An interview series featuring TOLREMO's CEO Stefanie Flückiger-Mangual discussing her journey and scientific work in drug resistance in cancer therapy.
Innovator of the Year 2022
Stefanie Flückiger-Mangual received the Innovator of the Year award at the Female Innovation Forum for her work in cancer drug resistance.